Spontaneous Phenotypic and Molecular Blood Remission in a Case of Chronic Lymphocytic Leukaemia

Bernard, Marc; Drénou, Bernard; Pangault, Céline; Dauriac, Charles; Fauchet, R.; LePrisé, Pierre-Yves; Lamy, Thierry

doi:10.1046/j.1365-2141.1999.01738.x

Cited by 9 publications

(5 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The finding of a low proportion of CD23+ cells being correlated with a high absolute lymphocyte count may be due to the pool of circulating lymphocytes being composed of differing proportions of normal and malignant cell subpopulations, with differences in this ratio in the early and advanced stages of the disease. In the initial phases of B-CLL, characterized using the classical criteria (Rai system) with a normal or moderately increased B lymphocyte count, most circulating cell subpopulations remain undisturbed [4,37]. Thus when the Binet A B-CLL patients were analysed, we found a relatively high percentage of CD23 membrane molecule expression and low PBLs [12,15,21], though there were no significant differences between the individual patients within the group.…”

Section: Discussionmentioning

confidence: 73%

Analysis of CD23 antigen expression in B-chronic lymphocytic leukaemia and its correlation with clinical parameters

Jurišić

Čolović²,

Kraguljac³

et al. 2008

Med Oncol

View full text Add to dashboard Cite

B-Chronic lymphocytic leukaemia (B-CLL) is a monoclonal malignancy characterized by an accumulation of terminally differentiated small and anergic B lymphocytes in the blood, bone marrow and other tissues. CD23 antigen, a trans-membrane glycoprotein, promotes the activation and proliferation of normal B lymphocytes and has an important role in the process of malignant transformation in B-CLL. This retrospective cohort study of 77 consecutive newly diagnosed B-CLL patients, 43 males, 34 females, median age of 62 years, examined CD23 expression and correlations with clinical parameters. CD23+ was negatively correlated with pro-lymphocyte infiltration of the bone marrow (P<0.01) and peripheral blood lymphocyte counts (P<0.001). Lower CD23 expression was correlated with lower serum immunoglobulin levels (P<0.05), especially IgG; while greater CD23 expression was positively correlated with higher CD5 levels. B-CLL patients with a percentage of CD23+ lymphocytes >40% had longer survival (92.8 months) than those expressing <40% (35.3 months) (P=0.001). CD23 is not uniformly expressed by lymphocytes in B-CLL patients, and the differences in expression are dependent on a number of clinical parameters, including the peripheral blood lymphocyte count and the degree of pro-lymphocyte infiltration of the bone marrow. CD23 expression is significantly decreased in patients with extremely high lymphocyte counts (PBL counts of >100 x 10(9)/l) and in the advanced stages of disease.

show abstract

Section: Discussionmentioning

confidence: 73%

Analysis of CD23 antigen expression in B-chronic lymphocytic leukaemia and its correlation with clinical parameters

Jurišić

Čolović²,

Kraguljac³

et al. 2008

Med Oncol

View full text Add to dashboard Cite

show abstract

“…The occurrence of a spontaneous regression in CLL, defined as the achievement of a clinical remission of the disease in the absence of any previous treatment (Ribera et al , 1987; Bernard et al , 1999; Gomez Garcia et al , 2002; Thomas et al , 2002; Upshaw & Callihan, 2002), although recognized since the 1970s (Han & Sokal, 1971; Wiernik, 1976), is rarely described in the literature (Ribera et al , 1987; Bernard et al , 1999; Gomez Garcia et al , 2002; Thomas et al , 2002; Upshaw & Callihan, 2002). A recent report described nine CLL cases with a spontaneous regression of the disease over an 11‐year follow‐up, in which the CLL clone was still immunophenotypically evident in the circulating lymphocyte population (Del Giudice et al , 2009).…”

Section: Expression Of Ighv3 Subgroup Genes and Good Prognosis In Cllmentioning

confidence: 99%

B‐cell receptor, clinical course and prognosis in chronic lymphocytic leukaemia: the growing saga of the IGHV3 subgroup gene usage

Giudice

Bomben

et al. 2011

Br J Haematol

View full text Add to dashboard Cite

The immunoglobulin heavy chain variable gene (IGHV) mutational status has been recognized as an important predictor of prognosis in chronic lymphocytic leukaemia (CLL) since 1999. More recently, other features of the B-cell receptor, such as stereotypy, have been identified as capable of refining the prognostic potential of IGHV status in the clinical assessment of CLL patients. In this context, different genes belonging to the IGHV3 subgroup, the most frequently used subgroup in CLL, have been shown to denote disease subsets that either display a bad prognosis (i.e. IGHV3-21, IGHV3-23) or are associated with particularly good clinical outcomes, including a highly stable/indolent clinical course, even prone to spontaneous regression (i.e. IGHV3-72, IGHV3-30). The present review focuses on the molecular and biological features of CLL-expressing specific genes belonging to the IGHV3 subgroup that are known to mark disease subsets with completely different clinical courses, and may be possibly related to CLL pathogenesis via antigen and/or superantigen involvement

show abstract

“…Twelve cases of spontaneous remission in CLL have been reported in the literature since 1970 (Schmidt et al , 1995; Bernard et al , 1999). Most of these cases showed a significant decrease in the blood lymphocyte count and, in a few cases, this was associated with blood or bone marrow remission.…”

Section: Discussionmentioning

confidence: 99%

Spontaneous clinical regression in chronic lymphocytic leukaemia

Thomas

Ribeiro²,

Shepherd

et al. 2002

Br J Haematol

View full text Add to dashboard Cite

show abstract

Spontaneous Phenotypic and Molecular Blood Remission in a Case of Chronic Lymphocytic Leukaemia

Cited by 9 publications

References 6 publications

Analysis of CD23 antigen expression in B-chronic lymphocytic leukaemia and its correlation with clinical parameters

Analysis of CD23 antigen expression in B-chronic lymphocytic leukaemia and its correlation with clinical parameters

B‐cell receptor, clinical course and prognosis in chronic lymphocytic leukaemia: the growing saga of the IGHV3 subgroup gene usage

Spontaneous clinical regression in chronic lymphocytic leukaemia

Contact Info

Product

Resources

About